Goldman Sachs on Angelalign Technology (6699.HK): H1 2026 Review: FY26 Case Guidance Raised on Strong Volume Growth; Overseas Breakeven Ahead of Schedule; Buy
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Goldman Sachs reiterates Buy on Angelalign Technology (6699.HK), 12-month target price HK$122.00, implying 35.6% upside from HK$90.00, and names it the top pick in its China medtech coverage. H1 2026 revenue reached US$231mn (+43% YoY) on roughly 316.6k total cases (+40%), gross margin rose 38bps to 62.7%, and adjusted net profit climbed 80% to US$35mn (15.2% margin, +310bps). Management raised FY26 case guidance to 700k (+32%, previously +25%): ~350k overseas (+37%) and ~350k in China (+27%, excluding upcoming VBP). Overseas revenue of US$118mn (+64.9%) on 168k cases (+43.4%) turned profitable ahead of schedule, with a 7.4% adjusted operating margin in H1 (excluding litigation costs and share-based payments) versus prior guidance of breakeven by end-2026, driven by direct-network scale effects, higher doctor repurchase and productivity, and back-office efficiency gains. Overseas gross margin slipped 146bps to 59.8% on design-center ramp. Management emphasizes pricing discipline—mid-single-digit increases were well absorbed—and targets high-single-digit overseas share in 2026, contrasting its orthodontist focus with Align Technology's GP/DSO approach. Dividends totaled HK$4.57 per share, including HK$4.10 special, echoing 2H25's HK$4.99 special payout; litigation shows no observable business impact.